• Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, oral treatments of cancer, acute kidney injury and other serious illnesses.
• Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.

READ MORE

• Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, breast cancer, pancreatic cancer, and prevention of acute kidney injury in seriously ill patients.

READ MORE

June 2023 – Cantex Pharmaceuticals announced that it obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline.

May 2023 – Cantex Pharmaceuticals announced today that the USPTO has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon. This patent will expire in 2042.

April 2023 – Cantex Pharmaceuticals and Michigan Medicine, a part of the University of Michigan, announced the initiation of a randomized double-blind, placebo-controlled, multicenter, phase 2/3 clinical study to evaluate the safety and efficacy of azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19.

READ ALL NEWS